INOVIQ Completes Disease Specificity Testing for Breast Cancer Blood Test; Shares Rise 8%

MT Newswires Live12-06

INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.

The test, which combines a monoclonal antibody with INOVIQ's SubB2M detection reagent, is proven to accurately identify CA15-3, a marker produced by cancer cells, improving the precision of cancer detection while minimizing false positives, the filing added.

The test showed 81% sensitivity and 93% specificity to detect breast cancer across all stages and is now effective for breast cancer monitoring, the filing said.

The test also effectively detected breast cancer with CA15-3 levels five times higher in patients than in healthy individuals, while returning negative results for 97.4% of non-cancer diseases.

Independent testing confirmed the INOVIQ test's superior specificity compared to an FDA-approved CA15-3 test, the filing added.

The company's next steps are to publish a scientific paper on the test to support partnerships, transfer the test to a high-throughput platform, conduct an in-clinic monitoring study, and secure a US laboratory partner for commercialization as a Laboratory Developed Test.

INOVIQ's shares rose 8% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489473185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489473185","market":"hk","top_or_hot":-1,"title":"INOVIQ Completes Disease Specificity Testing for Breast Cancer Blood Test; Shares Rise 8%","media":"MT Newswires Live","content":"<html><body><p> INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.</p><p>The test, which combines a monoclonal antibody with INOVIQ's SubB2M detection reagent, is proven to accurately identify CA15-3, a marker produced by cancer cells, improving the precision of cancer detection while minimizing false positives, the filing added.</p><p>The test showed 81% sensitivity and 93% specificity to detect breast cancer across all stages and is now effective for breast cancer monitoring, the filing said.</p><p>The test also effectively detected breast cancer with CA15-3 levels five times higher in patients than in healthy individuals, while returning negative results for 97.4% of non-cancer diseases.</p><p>Independent testing confirmed the INOVIQ test's superior specificity compared to an FDA-approved CA15-3 test, the filing added.</p><p>The company's next steps are to publish a scientific paper on the test to support partnerships, transfer the test to a high-throughput platform, conduct an in-clinic monitoring study, and secure a US laboratory partner for commercialization as a Laboratory Developed Test.</p><p>INOVIQ's shares rose 8% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INOVIQ Completes Disease Specificity Testing for Breast Cancer Blood Test; Shares Rise 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINOVIQ Completes Disease Specificity Testing for Breast Cancer Blood Test; Shares Rise 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.The test, which combines a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489473185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489473185","pubTimestamp":1733463334,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.The test, which combines a monoc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","IIQ.AU":"INOVIQ LTD"},"translate_title":"INOVIQ完成乳腺癌血液检测的疾病特异性检测；股价上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IIQ.AU":0.9},"content_text":"INOVIQ (ASX:IIQ) has completed disease specificity testing for its blood test designed to detect breast cancer, according to a Friday filing with the Australian bourse.The test, which combines a monoclonal antibody with INOVIQ's SubB2M detection reagent, is proven to accurately identify CA15-3, a marker produced by cancer cells, improving the precision of cancer detection while minimizing false positives, the filing added.The test showed 81% sensitivity and 93% specificity to detect breast cancer across all stages and is now effective for breast cancer monitoring, the filing said.The test also effectively detected breast cancer with CA15-3 levels five times higher in patients than in healthy individuals, while returning negative results for 97.4% of non-cancer diseases.Independent testing confirmed the INOVIQ test's superior specificity compared to an FDA-approved CA15-3 test, the filing added.The company's next steps are to publish a scientific paper on the test to support partnerships, transfer the test to a high-throughput platform, conduct an in-clinic monitoring study, and secure a US laboratory partner for commercialization as a Laboratory Developed Test.INOVIQ's shares rose 8% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489473185"}